Voyager Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor conferences.
- SVB Leerink 11th Annual Global Healthcare Conference, company presentation, Feb. 18, 2022, 9:20 a.m. ET
- Cowen 42nd Annual Health Care Conference, corporate panel discussion, Mar. 9, 2022, 12:50 p.m. ET
The sessions may be accessed from the Investors section of Voyager’s website at . Replays of the webcasts will be archived on the Company's website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
Investor Inquiries:
Media Inquiries:
Scott Santiamo
